NCT07381361

Brief Summary

The aim of this study was to evaluate the efficacy of photobiomodulation therapy and alpha-lipoic acid in the treatment of burning mouth syndrome by symptom assessment with visual analogue scale.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 10, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2026

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

January 25, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 2, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

March 10, 2026

Completed
Last Updated

February 3, 2026

Status Verified

January 1, 2026

Enrollment Period

10 months

First QC Date

January 25, 2026

Last Update Submit

January 30, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Visual Analogue Scale (VAS)

    The Visual Analogue Scale (VAS) will be used to assess the intensity of the patient's pain. The scale ranges from 0 to 10, where 0 represents "no pain" (the best possible outcome) and 10 represents "the worst pain imaginable" (the worst possible outcome). Therefore, higher scores indicate a worse outcome (greater pain intensity). During the interview or telephone follow-up, the patient will be asked to report the number that best describes their pain.

    Baseline and 2 weeks after intervention or observation

Study Arms (2)

PBMT group

EXPERIMENTAL

Burning mouth syndrome (BMS) patients in PBMT group were provided with BMS disease explanation and psychological counseling. They will receive low-energy laser therapy with an energy density of 5 J/cm² and a power of 0.1/0.5 W for a consecutive period of 2 weeks, 5 days per week.

Other: Low Level Laser Therapy

ALA group

ACTIVE COMPARATOR

Burning mouth syndrome (BMS) patients in the ALA group were provided with BMS disease explanation and psychological counseling. Then they took α-lipoic acid (ALA) 3 times a day, after meals, 200 mg each time, for 2 consecutive weeks.

Drug: Alpha Lipoic Acid

Interventions

Energy density: 5 J/cm² Power: 0.1/0.5 W Course of treatment: 2 consecutive weeks, 5 days per week.

Also known as: PBMT, LLLT, Photobiomodulation Therapy
PBMT group

Dosage: 600-800 mg ALA Course of treatment: 2 consecutive weeks, 3 times per day

ALA group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged 18 to 75 years
  • Diagnosis of Burning Mouth Syndrome (BMS) according to the 3rd edition of the International Classification of Headache Disorders (ICHD-3)
  • Daily intraoral burning or dysesthesia lasting for more than 2 hours for over 3 months
  • Normal oral mucosa and sensory testing
  • Condition not better accounted for by another ICHD-3 diagnosis

You may not qualify if:

  • Other oral mucosal diseases, such as oral leukoplakia or oral lichen planus
  • Diabetes with poor blood glucose control
  • Hematological diseases
  • Pregnancy or lactation
  • Severe mental disorders preventing cooperation with treatment
  • Heart failure (New York Heart Association class III-IV)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West China Hospital of Stomatology, Sichuan University

Chengdu, Sichuan, 610041, China

Location

MeSH Terms

Conditions

Burning Mouth Syndrome

Interventions

Low-Level Light TherapyThioctic Acid

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

Laser TherapyTherapeuticsPhototherapyCarboxylic AcidsOrganic ChemicalsThiophenesSulfur CompoundsCoenzymesEnzymes and CoenzymesFatty AcidsLipids

Study Officials

  • Lu Jiang, MD

    Sichuan University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

January 25, 2026

First Posted

February 2, 2026

Study Start

April 10, 2025

Primary Completion

January 20, 2026

Study Completion

March 10, 2026

Last Updated

February 3, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations